Kelowna, British Columbia– January 22, 2020 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that it has reached a new definitive agreement to provide its patented DehydraTECHTM technology…
Lexaria is technology for improved delivery of bioactive compounds.
CSE:LXX; OTCQX:LXRP
[stock_market_widget type=”single” symbol=”LXX.CN” template=”header” color=”blue” refresh_frequency=”0″] [stock_market_widget type=”single” symbol=”LXRP” template=”header” color=”blue” refresh_frequency=”0″]
Welcome to Lexaria Bioscience Corp.
Lexaria Bioscience Corp. (CSE:LXX; OTCQX:LXRP) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.
Lexaria’s DehydraTECHTM delivery technology is protected by a robust suite of patents granted or pending worldwide and is proven effective in multiple international studies in greatly assisting rapidity and quantity of absorption of a range of lipophilic (i.e., fat-soluble), bioactive molecules. By significantly enhancing the performance and experience with oral ingestion, Lexaria’s DehydraTECH delivery technology offers a viable and often healthier alternative to other delivery methods for bioactive substances in widespread use today such as inhalational delivery through smoking.
About DehydraTECH
Lexaria’s patented technology, DehydraTECH™ delivers these important benefits:
Masks taste/odor
Eliminates the strong tastes/odors of lipophilic compounds, without the need for unwanted sugar or sweeteners
Reduces time of onset
Effects are felt within 15-20 min vs. 60-120 min.
Avoids first-pass liver metabolism
Initial testing indirectly evidences DehydraTECH may deliver ingested molecules through the lymphatic system instead of being subject to immediate “first pass” liver exposure, potentially mitigating unwanted side effects and reducing liver biotransformation.
Increases bio-absorption
Bio-absorption increases up to 3 – 10X, to equate or exceed that of other routes of administration like inhalational delivery.
Lexaria’s disruptive new technology DehydraTECH can be licensed to improve existing drug delivery through orally-ingested products; or create revolutionary new ones.
DehydraTECH Commercial Applications
Lexaria’s DehydraTECH™ is designed specifically for formulating and delivering lipophilic (i.e. fat-soluble) drug payloads. It is patented or patent-pending for use with a broad range of bioactive molecules, including but not limited to:
Latest News
Lexaria Biosciences and Cannadips CBD reached definitive Technology Licensing agreement for CBD Oral Pouch & Dip Category
Kelowna, British Columbia– January 14, 2020 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that it has reached a definitive agreement to provide its patented DehydraTECHTM technology to…
Letter From the CEO (Long Version)
Lexaria Bioscience Corp (“Lexaria”, or the “Company”) is a global biotech leader in developing and implementing advanced technologies to better deliver Active Pharmaceutical Ingredients (“APIs”) into the human body for faster and more efficacious use. From humble beginnings with only…